KBI Biopharma, Inc.

Form 483 issued December 3, 2021 · Boulder, Colorado

Inspection
Nov 30 – Dec 3, 2021
Observations
2
Pages
3
FEI number
3011326133

In short: On December 3, 2021, FDA issued a Form 483 with 2 observations to KBI Biopharma, Inc. in Boulder, Colorado (FEI 3011326133) after an inspection that ran Nov 30 – Dec 3, 2021. The investigators were Michael A. Charles and Nicholas L. Hunt. Most observations concern quality system and facilities & equipment.

At a glance

Quality system and facilities & equipment account for 2 of 2 observations.

Quality system1
Facilities & equipment1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Investigations conducted are not always complete to include systematic investigations of root causes to identify sources…

  2. 02

    Procedures for maintenance of…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at KBI Biopharma, Inc.?

FDA listed 2 observations on this Form 483, mostly about quality system and facilities & equipment. The opening words of each observation are shown on this page.

Who inspected KBI Biopharma, Inc.?

Michael A. Charles and Nicholas L. Hunt are named on this Form 483, for the inspection of Nov 30 – Dec 3, 2021. Each investigator has a profile showing what they cite most.

When was KBI Biopharma, Inc. inspected by FDA?

The inspection ran Nov 30 – Dec 3, 2021, and the Form 483 is dated December 3, 2021.

How do I get the full Form 483 for KBI Biopharma, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free